This paper aims at seeking consensus whether Donepezil should be prescribed in preference to other available drugs for the treatment of Alzheimer’s disease. Donepezil is the generic name for the drug known by the brand name as Aricept. This drug has been in use for therapeutic purposes since its approval by FDA in 1996 in which it is used to treat memory loss (dementia) in patients suffering from Alzheimer's disease.
According to the pathophysiology of Alzheimer's disease, it has been documented that this disease is characterized with a brain disorder referred to as dementia. This condition affects the memory; thus, causing difficulties in communicating, thinking and remembering. It is also known to cause noticeable changes in personality and mood. Therefore, Alzheimer's disease causes inability in performing daily activities owing to the slow destruction of the memory.
It is for this clinical condition that Donepezil is used in order to improve mental function. Some of the most principal mental functions that are improved by Donepezil include memory, speaking, thinking, communicating, attention, and interpersonal interactions. Despite the ability of Donepezil to improve brain functioning by treating dementia, it is worth noting that this drug does not cure Alzheimer's disease.
Table of Contents
1. Introduction
2. Pharmacological Mechanism of Donepezil
3. Comparison with Alternative Alzheimer’s Drugs
4. Side Effects and Contra-indications
5. Formulation and Dosage
6. Clinical Preference and Efficacy Evaluation
7. Conclusion
Research Objectives and Core Themes
The primary objective of this paper is to evaluate the clinical efficacy and suitability of Donepezil compared to other pharmacological interventions in the treatment of Alzheimer's disease to determine its status as a preferred therapeutic agent.
- Mechanisms of action of cholinesterase inhibitors versus NMDA antagonists.
- Comparative analysis of side-effect profiles and contra-indications.
- Evaluation of dosage convenience and patient compliance factors.
- Assessment of drug stability and interaction with dietary habits.
- Clinical rationale for first-line versus second-line treatment categorization.
Excerpt from the Book
Pharmacological Mechanism and Therapeutic Goals
Donepezil is a cholinesterase inhibitor; thus, it inhibits the activity of acetylcholinesterase enzyme which is responsible for the destruction of acetylcholine. Acetylcholine is a neurotransmitter which is released into the synaptic cleft to transmit impulses between adjacent nerve cells. Alzheimer's disease has been found to be caused by the deficiency of neurotransmitters which are used by the nerve cells in the brain for intercellular communication. Therefore, the inhibition of acetylcholinesterase by donepezil ensures the presence of adequate levels of acetylcholine which aid in impulse transmission; thus normalizing the brain’s mental function. Clinical studies confirm that donepezil increases the concentration of acetylcholine, and this is the principal pharmacokinetic effect of the drug in improving the symptoms of Alzheimer's disease (Saltiel, 2014). However, this drug has not been found to slow the progression of the disease (Linda, Juergen and Bludau, 2011).
Currently, there are alternative drugs which are used to treat the same condition as donepezil. These drugs include galantamine (Razadyne), rivastigmine (Exelon), tacrine (Cognex), and memantine (Namenda). All these drugs are cholinesterase inhibitors except memantine and their mode of action is similar to that observed with donepezil. However, it is worth noting that these drugs have different pharmacological properties. Therefore, they manifest different side-effects and efficacy (Bentué-Ferrer, Tribut, Polard & Allain, 2003).
Summary of Chapters
1. Introduction: Outlines the pathophysiology of Alzheimer’s disease and introduces Donepezil as a treatment for managing dementia symptoms.
2. Pharmacological Mechanism of Donepezil: Explains the role of Donepezil as a cholinesterase inhibitor in stabilizing acetylcholine levels for neural communication.
3. Comparison with Alternative Alzheimer’s Drugs: Reviews competing medications like galantamine and memantine, highlighting their distinct pharmacological profiles.
4. Side Effects and Contra-indications: Details the common and severe health risks associated with Donepezil and identifies specific patient groups for whom the drug is contraindicated.
5. Formulation and Dosage: Examines the practical administration of the drug, focusing on how tablet forms and daily dosage frequency improve patient compliance.
6. Clinical Preference and Efficacy Evaluation: Argues for the prioritization of Donepezil as a first-line treatment due to its balanced efficacy and safety profile.
7. Conclusion: Summarizes the findings, asserting Donepezil as the current gold standard in managing Alzheimer’s symptoms despite the lack of a curative solution.
Keywords
Donepezil, Alzheimer's disease, dementia, cholinesterase inhibitor, acetylcholine, memantine, pharmacokinetics, drug efficacy, side effects, patient compliance, neurotransmitters, clinical pharmacology, neurodegeneration.
Frequently Asked Questions
What is the primary focus of this research?
The paper examines the therapeutic role of Donepezil in managing the symptoms of Alzheimer's disease and evaluates its clinical advantages compared to other available pharmacological treatments.
What are the central thematic pillars of this study?
The study centers on the mechanism of action, side-effect profiles, comparative efficacy, dosage convenience, and the clinical rationale for designating Donepezil as a first-line treatment.
What is the main research question addressed?
The research seeks to establish whether there is a clinical consensus for prescribing Donepezil in preference to alternative drugs for Alzheimer's patients.
Which scientific methodology is employed?
The paper utilizes a comparative pharmacological analysis, synthesizing clinical data and literature reviews to weigh the pros and cons of various dementia-treating agents.
What is the primary content of the main body?
The main body provides a detailed breakdown of pharmacological interactions, a comparative assessment of side effects, analysis of drug formulations, and a critical evaluation of drug efficacy.
Which keywords characterize this paper?
Key terms include Donepezil, Alzheimer's disease, dementia, cholinesterase inhibitor, acetylcholine, drug efficacy, and patient compliance.
Why is Donepezil considered a first-line treatment?
Donepezil is preferred due to its approval across all stages of Alzheimer's, its convenient once-daily dosage, and its favorable efficacy-to-safety profile compared to older drugs like tacrine.
How does Memantine differ from Donepezil in its mechanism?
While Donepezil is a cholinesterase inhibitor that affects acetylcholine, Memantine acts as an NMDA antagonist, primarily blocking the action of glutamate.
Does Donepezil cure Alzheimer's disease?
No, the paper clarifies that while Donepezil improves cognitive function and symptoms, it does not cure the disease or slow its underlying progression.
Why is tacrine no longer recommended?
Tacrine is no longer prescribed due to its significant hepatotoxicity and the potential for severe liver damage.
- Quote paper
- Patrick Kimuyu (Author), 2018, Questions on the Prescription of Donepezil in the Treatment of Alzheimer's Disease, Munich, GRIN Verlag, https://www.grin.com/document/388474
